Krishan Vikas made history on Wednesday (29) when he became the first Indian to win three Asian Games boxing medals.
But the nation's women, devoid of the legendary five times world champion "Magnificent" Mary Kom, will go home empty-handed for the first time since their sport was introduced in 2010.
The 2010 gold medallist in Guangzhou, Vikas won a bronze four years ago and had to draw on all his experience in Jakarta after suffering a nasty cut over his right eye early in his middleweight (75kg) quarter-final against China's Erbieke Tanglatihan.
India's last woman standing, flyweight Sarjubala Devi, could not emulate Kom -- who won gold in the same 51kg division four years ago -- as she lost on unanimous points to China's Chang Yuan.
Kom is skipping this year's Games to concentrate on November's World Championships in Delhi.
Vikas had to dig deep and produce a strong finish to edge a 3-2 split decision and guarantee at least a bronze medal.
"It's quite satisfying to come through that and be the first Indian to win three medals," Vikas told AFP. "Especially as I suffered a serious injury. Yeah, I'm very happy."
The 26-year-old fought brilliantly on the counter for the last two rounds as he protected his rapidly swelling eye.
"I hit him with some hard shots. But with my eye injured I was not able to get in close and had to keep my distance," said Vikas. "Without that cut I would have beaten him 5-0."
Vikas has a tougher task ahead if he wants a shot at a second Asian Games gold to add to his Commonwealth Games title won earlier this year in Australia.
Lying in wait in the semi-final is big puncher Abilkhan Amankul of Kazakhstan, who produced the performance of the day to outclass Taiwan's Kan Chia-wei.
Kazakhstan were the dominant boxing force at the last Asian Games, winning six golds, two silver and two bronzes in Incheon.
But they have punched uncharacteristically below their weight in Jakarta with Amankul just their second boxer to reach the medal bouts.
- 'He was smart' -
Amankul was mightily impressive in dismantling Kan, who did well to last the distance after a 30-25 battering on all five scorecards.
Filipino 2016 World Youth Champion Carlo Paalam, 20, pulled off the best win of his senior career when he rallied to take a 4-1 split decision against another Kazakhstani, Temirtas Zhussupov.
Light flyweight (49kg) Paalam was delighted at securing at least a bronze at his first Asian Games and was not surprised that the judges couldn't agree.
"Of course it went to a split decision. He was really good," Paalam told AFP. "He is number one in Kazakhstan. He has fought in the Olympics.
"He was smart, really experienced. I tried to ride it out, to use ring strategy."
Paalam will now face Amit, who goes by one name, for a place in the final after the 22-year-old became the first Indian fighter to book a last-four berth, comprehensively outboxing North Korean Kim Jan Ryong.
Amit said he had drawn from the experience of veterans in the India camp such as light welterweight Manoj Kumar, 31, who has been to two Asian and two Olympic Games.
"There are many other senior boxers who motivate me and I learn from them," he said. "Manoj (Kumar)is my roommate and he guides me, he shows me how to go about it."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.